The research aiming at the development of high-quality pharmaceutical products -both generic medicines and innovative new formulations- is at the core business of our corporation. The investment in Research and Development will differentiate Rontis from competing companies active in the field, considering that Rontis will not only sell drugs but will develop and produce the medicines. In this manner, our company will actively participate in the whole process from development and production to trading, and consequently will determine, completely control and will be able to guarantee the specifications of the products. The pharmaceutical division is following the successful model Rontis established with its Medical Device Division which was based in R&D.
The development of new pharmaceutical products, as well as the development of new technologies of drug administration is a key objective for the pharmaceutical department of our company. The division’s activities are supported by a high-qualified research group of people, who explore and evaluate patents, design, develop and inspect the test batches and the certification batches of all pharmaceutical forms, conduct bioequivalence studies and stability tests of new products, meeting legal requirements, both within and outside Europe. The products will be produced in our state-of-the-art pharmaceutical plant and will be the basis to expand our partnerships at the international level.
The new products will cover a wide range of therapeutic categories with drugs treating a large number of indications. The common denominator in Research and Development is the drive for innovation with a clear preference to the complex composition and advanced formulations, ensuring at the same time products quality and effectiveness.
In this context, we are very pleased to announce the successful completion of the development of Rontis’ first pharmaceutical product, which has etoricoxib as the active ingredient, it is a film coated tablet and it’s classified in therapeutic group of non-steroidal anti-inflammatory drugs. The development of this product was achieved in a very short period of time through the excellent cooperation of all involved departments of our company. Our colleagues in our pharma plant, who managed to achieve the certification of the product always faithful to the international standards of pharmaceutical legislation, deserve a special mention.
Despite the fact that we are still in the early stages of promoting our product in the international pharmaceutical market, there is a significant interest from international companies. More specifically, the first commercial agreement was signed recently with a large international foreign firm.
Lastly, we had the opportunity to present the aforementioned product as well as the ongoing developments of our R&D lab at the Global Pharmaceutical Exchibition, CPhI, in Paris, on October 7-9, in which we participated as exhibitors.